Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Lonasen 10-(4-ethylpiperazin-1-yl)- 12-(4...

Synonyms: Blonanserin, CHEMBL178803, SureCN119669, cc-715, ACN-S002533, ...

Matsuda, M. et al., Nagai, T. et al., Noda, Y. et al., Oka, M. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of D01176

Unlike haloperidol (3 mg/kg p.o.), AD-5423 (10 mg/kg p.o.) did not cause hyperthermia in combined treatment with veratrine (into the preoptic anterior hypothalamus).(ABSTRACT TRUNCATED AT 250 WORDS)[1]
However, different results were obtained between the effects of AD-5423 and haloperidol in possible animal models of tardive dyskinesia and malignant syndrome [1].

High impact information on D01176

In addition, AD-5423 was only a weak inhibitor of DA, 5-HT and noradrenaline uptake systems [2].
The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia, was attenuated by AD-5423 but not by haloperidol [3].
In order to investigate the pharmacokinetics of AD-5423, a simple and sensitive high-performance liquid chromatographic (HPLC) method has been developed for the simultaneous determination of AD-5423 and its two N-oxidized metabolites (N-desethyl AD-5423 and AD-5423 N-oxide) in plasma [4].

Associations of D01176 with other chemical compounds

The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT(2) and a dopamine D(2) receptor antagonist, was evaluated using animal models of schizophrenia [3].

Analytical, diagnostic and therapeutic context of D01176

After pretreatment of a plasma sample by solid-phase extraction, AD-5423 and its metabolites were analyzed on a HPLC with fluorescence detection (335/410 nm) [4].
Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detection [4].

References

Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. Noda, Y., Kurumiya, S., Miura, Y., Oka, M. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. Oka, M., Noda, Y., Ochi, Y., Furukawa, K., Une, T., Kurumiya, S., Hino, K., Karasawa, T. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice. Nagai, T., Noda, Y., Une, T., Furukawa, K., Furukawa, H., Kan, Q.M., Nabeshima, T. Neuroreport (2003) [Pubmed]
Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detection. Matsuda, M., Sakashita, M., Yamaguchi, T., Fujii, T. Journal of pharmaceutical and biomedical analysis. (1997) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg